News & Views
Partnership to Develop Protein Formulation for Cartilage Repair
Nov 07 2014
Nanomedicine R&D company Carlina Technologies (Angers, France), has signed an agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.
The product development process uses the PEPTIDOTTM technology platform for encapsulation of therapeutic peptides and proteins without altering their structure, therefore maintaining their full biological activity. Initially targeting off-patent drugs, Carlina currently offers improved treatments for diabetes, growth hormone deficiencies and a tumour-targeted anticancer nanomedicine to treat companion animals with cancer. It also provides R&D services in formulation development with out-licensing opportunities to improve the efficacy and safety of proprietary drugs from the pharma & veterinary industries.
This agreement provides an option for Laboratoires Genévrier spin-off GenBiotech, to acquire worldwide rights on the PEPTIDOT platform to develop, sub-license, or commercialise this product specifically for cartilage repair for animal health.
“Nanomedicines and their development programs are becoming critical to the pharmaceutical industry. Carlina Technologies has been working with GenBiotech for a number of years and we are delighted that our collaboration will be expanded with a partnership agreement,” said Olivier Meyer, President & CEO of Carlina Technologies. “This collaboration will contribute to the development of an important protein in the much needed bone cartilage repair area.”
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China